Prophase Labs (PRPH) Q3 2024 earnings summary

Executive summary

• Aggressive capital raise executed to support launches of DNA Complete and DNA Expand, and to ramp up Pharmaloz Manufacturing (PMI) for the holiday season.

• Net revenue for Q3 2024 was $3.1 million, down from $8.4 million in Q3 2023, driven by declines in diagnostic services and consumer products due to reduced COVID-19 testing volumes and lower consumer product sales.

• Net loss for Q3 2024 was $6.6 million ($0.35 per share), compared to a net loss of $5.1 million ($0.30 per share) in Q3 2023, reflecting lower revenues and higher interest expenses.

• Strategic focus on reducing overhead by at least $6 million and potentially satisfying over $5 million in payables before year-end.

• Multiple potential liquidity events anticipated, including government receivables, BE-Smart test partnerships, and a possible sale of PMI.

Financial highlights

• PMI expected to generate $15 million in revenue and $5 million+ in earnings over the next 12 months from the first manufacturing line.

• Second manufacturing line for PMI could add $20–$25 million in annual revenue, with a five-year contract under negotiation.

• DNA Expand projected as a high-margin, cash-generating business with potential to reach $50 million in annual revenue if 1 million out of 26 million ancestry customers are converted.

• Gross margin for Q3 2024 was negative 5.2%, compared to 27.8% in Q3 2023; for the nine months, gross margin was negative 11.6% versus 47.2% in the prior year.

• Adjusted EBITDA for Q3 2024 was $(4.4) million, compared to $(2.5) million in Q3 2023.

Outlook and guidance

• Anticipates at least $5 million in earnings from Pharmaloz next year, with a total $11 million positive cash swing from cost reductions and payables management.

• Significant sequential improvement in revenues and EBITDA expected in Q4 2024 and beyond, driven by subsidiary growth and strategic initiatives.

• Expects to break out DNA Complete and DNA Expand sales in Q4, with initial traction targeted during the holiday season.

• Plans to commercialize BE-Smart esophageal cancer test within a year, with potential for rapid acceleration if FDA allows LDT route.

• Company plans to reduce overhead and expenses by approximately $6 million annually in 2025 to focus on core assets.